We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced "Eosinophilic Fasciitis-Like" Case and a Review of the Literature.
- Authors
Salamaliki, Christina; Solomou, Elena E.; Liossis, Stamatis-Nick C.
- Abstract
Immune checkpoint inhibitors are a promising new therapeutic strategy in oncology that aims to eliminate cancer cells by enhancing patients' immune response against tumor antigens. Despite their beneficial effects, immune checkpoint inhibitors are also responsible for a plethora of autoimmune manifestations, known as immune-related adverse events. We present a case of eosinophilic fasciitis-like disorder in an 81-year-old patient treated with the programmed death cell protein 1 inhibitor pembrolizumab for non-small-cell lung cancer. The patient developed characteristic indurated skin lesions in his limbs after 1½ years of treatment with pembrolizumab and a typical "groove sign." Raynaud's syndrome was absent. A full-thickness biopsy confirmed the clinical diagnosis of an "EF-like" condition. Neither peripheral eosinophilia nor eosinophilic infiltrates in the skin biopsy were found. His symptoms improved after a 2.5-month CPI discontinuation and treatment with 16 mg of methylprednisolone slowly tapered to a dose of 4 mg. Eosinophilic fasciitis is a rare immune-related adverse event of CPI treatment; our literature search identified only 12 cases that fulfill the criteria of EF in patients receiving CPIs.
- Subjects
FASCIITIS; IMMUNE checkpoint inhibitors; APOPTOSIS; NON-small-cell lung carcinoma; LITERATURE reviews; TUMOR antigens
- Publication
Rheumatology & Therapy, 2020, Vol 7, Issue 4, p1045
- ISSN
2198-6576
- Publication type
Article
- DOI
10.1007/s40744-020-00246-z